ALNY:NSD-Alnylam Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 243.25

Change

+0.99 (+0.41)%

Market Cap

USD 31.66B

Volume

0.25M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.91 (+0.72%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

-0.66 (-0.09%)

USD 84.94B
ARGX argenx NV ADR

+1.67 (+0.27%)

USD 36.54B
BGNE BeiGene Ltd

+3.92 (+2.21%)

USD 20.24B
UTHR United Therapeutics Corporatio..

-2.78 (-0.76%)

USD 16.18B
MRNA Moderna Inc

+0.68 (+1.72%)

USD 16.10B
RPRX Royalty Pharma Plc

-0.02 (-0.08%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.33 (+1.77%)

USD 13.67B
INCY Incyte Corporation

+0.07 (+0.10%)

USD 13.52B
INSM Insmed Inc

-0.06 (-0.08%)

USD 13.20B

ETFs Containing ALNY

MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 4.73 % 0.00 %

+0.08 (+0.49%)

USD 5.35M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 3.33 % 0.00 %

N/A

USD 0.52B
IBBQ Invesco Nasdaq Biotechnol.. 3.32 % 0.00 %

+0.09 (+0.49%)

USD 0.04B
2B70:F iShares NASDAQ US Biotech.. 3.31 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.76 % 0.00 %

N/A

USD 0.04B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

N/A

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
EQJS:LSE Invesco NASDAQ Next Gener.. 2.10 % 0.00 %

+13.25 (+0.49%)

USD 0.05B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.10 % 0.00 %

N/A

USD 0.05B
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

+0.14 (+0.49%)

N/A
LABU Direxion Daily S&P Biotec.. 1.66 % 1.14 %

+0.18 (+0.49%)

USD 0.82B
TMFX Motley Fool Next Index ET.. 1.59 % 0.00 %

+0.14 (+0.49%)

USD 0.03B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

+4.60 (+0.49%)

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

N/A

N/A
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.07 (+0.49%)

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.29 (+0.49%)

USD 0.08B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

+0.68 (+0.49%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.34 (+0.49%)

USD 6.91B
LABS 0.00 % 0.45 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+0.49%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.49%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+0.49%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.09 (+0.49%)

N/A
IUSF:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+2.88 (+0.49%)

USD 0.29B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.00 % 0.00 %

+0.08 (+0.49%)

USD 0.29B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

+0.25 (+0.49%)

USD 0.69B
QQQN 0.00 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.10 (+0.49%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.08% 78% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.08% 78% C+ 78% C+
Trailing 12 Months  
Capital Gain 27.22% 77% C+ 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.22% 77% C+ 78% C+
Trailing 5 Years  
Capital Gain 106.55% 89% A- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.55% 89% A- 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 15.10% 61% D- 68% D+
Dividend Return 15.10% 61% D- 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.85% 89% A- 65% D
Risk Adjusted Return 54.21% 95% A 80% B-
Market Capitalization 31.66B 99% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.